Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Rating of “Buy” by Analysts

Share on StockTwits

Amicus Therapeutics, Inc. (NASDAQ:FOLD) has been assigned an average rating of “Buy” from the ten brokerages that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is $17.82.

A number of equities analysts have weighed in on FOLD shares. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Amicus Therapeutics in a research report on Thursday, November 21st. Cantor Fitzgerald restated an “overweight” rating on shares of Amicus Therapeutics in a research report on Thursday, October 17th. Cowen set a $31.00 target price on shares of Amicus Therapeutics and gave the company a “buy” rating in a research note on Thursday, October 10th. Zacks Investment Research upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $9.25 target price on the stock in a research note on Monday, November 4th. Finally, ValuEngine downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, December 4th.

Shares of NASDAQ:FOLD traded down $0.33 during mid-day trading on Friday, reaching $9.46. 3,329,562 shares of the company traded hands, compared to its average volume of 3,311,285. The company’s 50 day moving average price is $9.45 and its 200-day moving average price is $10.39. The firm has a market cap of $2.49 billion, a PE ratio of -7.11 and a beta of 1.57. The company has a debt-to-equity ratio of 0.36, a current ratio of 6.20 and a quick ratio of 6.10. Amicus Therapeutics has a 52 week low of $7.11 and a 52 week high of $14.61.

Amicus Therapeutics (NASDAQ:FOLD) last released its earnings results on Monday, November 11th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.32) by $0.08. Amicus Therapeutics had a negative net margin of 216.02% and a negative return on equity of 62.61%. The company had revenue of $48.80 million during the quarter, compared to analyst estimates of $48.05 million. During the same period in the prior year, the firm posted ($0.84) EPS. The firm’s quarterly revenue was up 136.9% compared to the same quarter last year. On average, research analysts predict that Amicus Therapeutics will post -1.27 earnings per share for the current fiscal year.

In related news, CEO John F. Crowley sold 20,000 shares of the firm’s stock in a transaction on Friday, November 8th. The shares were sold at an average price of $9.02, for a total transaction of $180,400.00. Following the completion of the transaction, the chief executive officer now directly owns 755,694 shares of the company’s stock, valued at $6,816,359.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO John F. Crowley sold 14,500 shares of the firm’s stock in a transaction on Friday, October 11th. The shares were sold at an average price of $8.01, for a total transaction of $116,145.00. Following the transaction, the chief executive officer now directly owns 735,694 shares of the company’s stock, valued at $5,892,908.94. The disclosure for this sale can be found here. Insiders have sold a total of 114,500 shares of company stock worth $1,094,945 in the last three months. 2.50% of the stock is owned by corporate insiders.

A number of hedge funds have recently made changes to their positions in the business. Point72 Hong Kong Ltd bought a new position in shares of Amicus Therapeutics during the 2nd quarter valued at about $49,000. US Bancorp DE lifted its position in shares of Amicus Therapeutics by 50.9% in the second quarter. US Bancorp DE now owns 4,896 shares of the biopharmaceutical company’s stock worth $61,000 after buying an additional 1,651 shares in the last quarter. Meeder Asset Management Inc. purchased a new stake in shares of Amicus Therapeutics in the second quarter worth about $73,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. bought a new position in Amicus Therapeutics during the second quarter valued at approximately $122,000. Finally, Weil Company Inc. bought a new position in Amicus Therapeutics during the second quarter valued at approximately $125,000.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.

Recommended Story: How to build a Fibonacci channel

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.